Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases
Clinical features of 40 lymphoproliferative neoplasm patients in the setting of systemic autoimmune diseases managed in the Clinic of Hematology during 1994–2006 were analyzed retrospectively. The classification of systemic autoimmune disease patients was as follows: 15 systemic lupus erythematosus—...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2012-09, Vol.29 (3), p.2207-2211 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2211 |
|---|---|
| container_issue | 3 |
| container_start_page | 2207 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 29 |
| creator | Suvajdzic, Nada Djurdjevic, Predrag Todorovic, Milena Perunicic, Maja Stojanović, Roksanda Novkovic, Aleksandra Mihaljevic, Biljana |
| description | Clinical features of 40 lymphoproliferative neoplasm patients in the setting of systemic autoimmune diseases managed in the Clinic of Hematology during 1994–2006 were analyzed retrospectively. The classification of systemic autoimmune disease patients was as follows: 15 systemic lupus erythematosus—SLE, 11 rheumatoid arthritis—RA, 12 Sjögren’s syndrome—SS, 1 scleroderma, and 1 dermatomyositis. Patients comprised 31 women and 9 men of mean age 55 years (range 33–76). Systemic autoimmune diseases preceeded the development of lymphoproliferative neoplasms in 37/40 (92.5%) patients. Mean latency period between the onset of systemic autoimmune diseases and lymphoproliferative neoplasms occurrence was significantly longer in RA (113 months) than in SLE (75 months) and SS patients (65 months)—
P
0.05. Our findings are in line with earlier reports showing a high proportion of patients with advanced disease, constitutional symptoms, extranodal manifestations, high grade histology, and low OS in the systemic autoimmune diseases setting. |
| doi_str_mv | 10.1007/s12032-011-0022-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1035102423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2748867831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-1fbfbcac7d37b663a7973804d1c9a41a84d4e6b1d02a0b5756e824cbb377ebf3</originalsourceid><addsrcrecordid>eNp1kUtrHDEQhEWwiZ8_IJcg8CWXidXSaLR7DIsTGwy--ODbIGl6dmXmZbXG8f77aNmNCQGfuqG_qi4oxr6A-A5CmGsCKZQsBEAhhJTF2yd2ClovC1DwdJR3pU0hdCVO2BnRc2ZAy-VndiLBaK2MPGWvqy4MwduO-42N1ieMgVLwxMeWTzYFHBLx3yFteLftp804xbELLcZ8ekU-4Dh1lnriYeBpg5wwpTCsd2raUsI-eG7nNIa-nwfkTSC0hHTBjlvbEV4e5jl7_HnzuLot7h9-3a1-3Bc-p0sFtK513nrTKOOqSlmzNGohygb80pZgF2VTYuWgEdIKp42ucCFL75wyBl2rztm3vW1O_TIjpboP5LHrbA4-Uw1CaRCylCqjV_-hz-MchxxuRxlpKi3KTMGe8nEkitjWUwy9jdsM1btO6n0nde6k3nVSv2XN14Pz7Hps3hV_S8iA3AOUT8Ma47-vP3L9Az5dmlc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1037276504</pqid></control><display><type>article</type><title>Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Suvajdzic, Nada ; Djurdjevic, Predrag ; Todorovic, Milena ; Perunicic, Maja ; Stojanović, Roksanda ; Novkovic, Aleksandra ; Mihaljevic, Biljana</creator><creatorcontrib>Suvajdzic, Nada ; Djurdjevic, Predrag ; Todorovic, Milena ; Perunicic, Maja ; Stojanović, Roksanda ; Novkovic, Aleksandra ; Mihaljevic, Biljana</creatorcontrib><description>Clinical features of 40 lymphoproliferative neoplasm patients in the setting of systemic autoimmune diseases managed in the Clinic of Hematology during 1994–2006 were analyzed retrospectively. The classification of systemic autoimmune disease patients was as follows: 15 systemic lupus erythematosus—SLE, 11 rheumatoid arthritis—RA, 12 Sjögren’s syndrome—SS, 1 scleroderma, and 1 dermatomyositis. Patients comprised 31 women and 9 men of mean age 55 years (range 33–76). Systemic autoimmune diseases preceeded the development of lymphoproliferative neoplasms in 37/40 (92.5%) patients. Mean latency period between the onset of systemic autoimmune diseases and lymphoproliferative neoplasms occurrence was significantly longer in RA (113 months) than in SLE (75 months) and SS patients (65 months)—
P
< 0.05. The most frequent lymphoproliferative neoplasms were non-Hodgkin’s lymphoma—NHL (35/40; 88%), diffuse large B-cell lymphoma (DBCL)—12 (34%), follicular lymphoma (FC)—7 (20%), small lymphocytic (SL), and marginal zone lymphoma (MZL)—5 (14%) each. The primary site of NHL was extranodal in 18/35 (51.5%) cases. Advanced disease on diagnosis (III + IV clinical stages), constitutional symptoms, and bulky disease were diagnosed in 27/35 (77%), 26/35 (74%), and 3/35 (8.5%) patients, respectively. The overall survival (OS) was as follows (months): DBCL-12, FC-63, SLL-60, and MZL-48. There was no association between the lymphoproliferative neoplasm histological subtype and the systemic autoimmune diseases type or antirheumatic treatment
P
> 0.05. Our findings are in line with earlier reports showing a high proportion of patients with advanced disease, constitutional symptoms, extranodal manifestations, high grade histology, and low OS in the systemic autoimmune diseases setting.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-011-0022-x</identifier><identifier>PMID: 21755372</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Autoimmune Diseases - complications ; Autoimmune Diseases - mortality ; Autoimmune Diseases - pathology ; Female ; Hematology ; Humans ; Internal Medicine ; Kaplan-Meier Estimate ; Lymphoproliferative Disorders - complications ; Lymphoproliferative Disorders - mortality ; Lymphoproliferative Disorders - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Retrospective Studies</subject><ispartof>Medical oncology (Northwood, London, England), 2012-09, Vol.29 (3), p.2207-2211</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><rights>Springer Science+Business Media, LLC 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-1fbfbcac7d37b663a7973804d1c9a41a84d4e6b1d02a0b5756e824cbb377ebf3</citedby><cites>FETCH-LOGICAL-c372t-1fbfbcac7d37b663a7973804d1c9a41a84d4e6b1d02a0b5756e824cbb377ebf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-011-0022-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-011-0022-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27913,27914,41477,42546,51308</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21755372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suvajdzic, Nada</creatorcontrib><creatorcontrib>Djurdjevic, Predrag</creatorcontrib><creatorcontrib>Todorovic, Milena</creatorcontrib><creatorcontrib>Perunicic, Maja</creatorcontrib><creatorcontrib>Stojanović, Roksanda</creatorcontrib><creatorcontrib>Novkovic, Aleksandra</creatorcontrib><creatorcontrib>Mihaljevic, Biljana</creatorcontrib><title>Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Clinical features of 40 lymphoproliferative neoplasm patients in the setting of systemic autoimmune diseases managed in the Clinic of Hematology during 1994–2006 were analyzed retrospectively. The classification of systemic autoimmune disease patients was as follows: 15 systemic lupus erythematosus—SLE, 11 rheumatoid arthritis—RA, 12 Sjögren’s syndrome—SS, 1 scleroderma, and 1 dermatomyositis. Patients comprised 31 women and 9 men of mean age 55 years (range 33–76). Systemic autoimmune diseases preceeded the development of lymphoproliferative neoplasms in 37/40 (92.5%) patients. Mean latency period between the onset of systemic autoimmune diseases and lymphoproliferative neoplasms occurrence was significantly longer in RA (113 months) than in SLE (75 months) and SS patients (65 months)—
P
< 0.05. The most frequent lymphoproliferative neoplasms were non-Hodgkin’s lymphoma—NHL (35/40; 88%), diffuse large B-cell lymphoma (DBCL)—12 (34%), follicular lymphoma (FC)—7 (20%), small lymphocytic (SL), and marginal zone lymphoma (MZL)—5 (14%) each. The primary site of NHL was extranodal in 18/35 (51.5%) cases. Advanced disease on diagnosis (III + IV clinical stages), constitutional symptoms, and bulky disease were diagnosed in 27/35 (77%), 26/35 (74%), and 3/35 (8.5%) patients, respectively. The overall survival (OS) was as follows (months): DBCL-12, FC-63, SLL-60, and MZL-48. There was no association between the lymphoproliferative neoplasm histological subtype and the systemic autoimmune diseases type or antirheumatic treatment
P
> 0.05. Our findings are in line with earlier reports showing a high proportion of patients with advanced disease, constitutional symptoms, extranodal manifestations, high grade histology, and low OS in the systemic autoimmune diseases setting.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Autoimmune Diseases - complications</subject><subject>Autoimmune Diseases - mortality</subject><subject>Autoimmune Diseases - pathology</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphoproliferative Disorders - complications</subject><subject>Lymphoproliferative Disorders - mortality</subject><subject>Lymphoproliferative Disorders - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Retrospective Studies</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUtrHDEQhEWwiZ8_IJcg8CWXidXSaLR7DIsTGwy--ODbIGl6dmXmZbXG8f77aNmNCQGfuqG_qi4oxr6A-A5CmGsCKZQsBEAhhJTF2yd2ClovC1DwdJR3pU0hdCVO2BnRc2ZAy-VndiLBaK2MPGWvqy4MwduO-42N1ieMgVLwxMeWTzYFHBLx3yFteLftp804xbELLcZ8ekU-4Dh1lnriYeBpg5wwpTCsd2raUsI-eG7nNIa-nwfkTSC0hHTBjlvbEV4e5jl7_HnzuLot7h9-3a1-3Bc-p0sFtK513nrTKOOqSlmzNGohygb80pZgF2VTYuWgEdIKp42ucCFL75wyBl2rztm3vW1O_TIjpboP5LHrbA4-Uw1CaRCylCqjV_-hz-MchxxuRxlpKi3KTMGe8nEkitjWUwy9jdsM1btO6n0nde6k3nVSv2XN14Pz7Hps3hV_S8iA3AOUT8Ma47-vP3L9Az5dmlc</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Suvajdzic, Nada</creator><creator>Djurdjevic, Predrag</creator><creator>Todorovic, Milena</creator><creator>Perunicic, Maja</creator><creator>Stojanović, Roksanda</creator><creator>Novkovic, Aleksandra</creator><creator>Mihaljevic, Biljana</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases</title><author>Suvajdzic, Nada ; Djurdjevic, Predrag ; Todorovic, Milena ; Perunicic, Maja ; Stojanović, Roksanda ; Novkovic, Aleksandra ; Mihaljevic, Biljana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-1fbfbcac7d37b663a7973804d1c9a41a84d4e6b1d02a0b5756e824cbb377ebf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Autoimmune Diseases - complications</topic><topic>Autoimmune Diseases - mortality</topic><topic>Autoimmune Diseases - pathology</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphoproliferative Disorders - complications</topic><topic>Lymphoproliferative Disorders - mortality</topic><topic>Lymphoproliferative Disorders - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suvajdzic, Nada</creatorcontrib><creatorcontrib>Djurdjevic, Predrag</creatorcontrib><creatorcontrib>Todorovic, Milena</creatorcontrib><creatorcontrib>Perunicic, Maja</creatorcontrib><creatorcontrib>Stojanović, Roksanda</creatorcontrib><creatorcontrib>Novkovic, Aleksandra</creatorcontrib><creatorcontrib>Mihaljevic, Biljana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suvajdzic, Nada</au><au>Djurdjevic, Predrag</au><au>Todorovic, Milena</au><au>Perunicic, Maja</au><au>Stojanović, Roksanda</au><au>Novkovic, Aleksandra</au><au>Mihaljevic, Biljana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>29</volume><issue>3</issue><spage>2207</spage><epage>2211</epage><pages>2207-2211</pages><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Clinical features of 40 lymphoproliferative neoplasm patients in the setting of systemic autoimmune diseases managed in the Clinic of Hematology during 1994–2006 were analyzed retrospectively. The classification of systemic autoimmune disease patients was as follows: 15 systemic lupus erythematosus—SLE, 11 rheumatoid arthritis—RA, 12 Sjögren’s syndrome—SS, 1 scleroderma, and 1 dermatomyositis. Patients comprised 31 women and 9 men of mean age 55 years (range 33–76). Systemic autoimmune diseases preceeded the development of lymphoproliferative neoplasms in 37/40 (92.5%) patients. Mean latency period between the onset of systemic autoimmune diseases and lymphoproliferative neoplasms occurrence was significantly longer in RA (113 months) than in SLE (75 months) and SS patients (65 months)—
P
< 0.05. The most frequent lymphoproliferative neoplasms were non-Hodgkin’s lymphoma—NHL (35/40; 88%), diffuse large B-cell lymphoma (DBCL)—12 (34%), follicular lymphoma (FC)—7 (20%), small lymphocytic (SL), and marginal zone lymphoma (MZL)—5 (14%) each. The primary site of NHL was extranodal in 18/35 (51.5%) cases. Advanced disease on diagnosis (III + IV clinical stages), constitutional symptoms, and bulky disease were diagnosed in 27/35 (77%), 26/35 (74%), and 3/35 (8.5%) patients, respectively. The overall survival (OS) was as follows (months): DBCL-12, FC-63, SLL-60, and MZL-48. There was no association between the lymphoproliferative neoplasm histological subtype and the systemic autoimmune diseases type or antirheumatic treatment
P
> 0.05. Our findings are in line with earlier reports showing a high proportion of patients with advanced disease, constitutional symptoms, extranodal manifestations, high grade histology, and low OS in the systemic autoimmune diseases setting.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>21755372</pmid><doi>10.1007/s12032-011-0022-x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2012-09, Vol.29 (3), p.2207-2211 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1035102423 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autoimmune Diseases - complications Autoimmune Diseases - mortality Autoimmune Diseases - pathology Female Hematology Humans Internal Medicine Kaplan-Meier Estimate Lymphoproliferative Disorders - complications Lymphoproliferative Disorders - mortality Lymphoproliferative Disorders - pathology Male Medicine Medicine & Public Health Middle Aged Oncology Original Paper Pathology Retrospective Studies |
| title | Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A56%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20of%20patients%20with%20lymphoproliferative%20neoplasms%20in%20the%20setting%20of%20systemic%20autoimmune%20diseases&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Suvajdzic,%20Nada&rft.date=2012-09-01&rft.volume=29&rft.issue=3&rft.spage=2207&rft.epage=2211&rft.pages=2207-2211&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-011-0022-x&rft_dat=%3Cproquest_cross%3E2748867831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1037276504&rft_id=info:pmid/21755372&rfr_iscdi=true |